Loading...
 
Mediterr J Rheumatol 2015; 26(2): 62-75
Symmetric and asymmetric dimethylarginines as biochemical markers of endothelial dysfunction and atherosclerosis in Rheumatoid Arthritis
Authors Information
1: Department of Rheumatology, Russels Hall Hospital, DudleyNHS FT, , United Kingdom
2: 4th Department of Internal Medicine, Ippokrateion Hospital, Thessaloniki, Greece
3: School of Sport, Health and Exercise Sciences, Bangor University, Gwynedd, Wales, United Kingdom
4: Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom
References
  1. Van Doornum S, Jennings GL, Wicks IP. Reducing the cardiovascular disease burden in rheumatoid arthritis. Med J Aust 2006; 184:287-90.
  2. Gonzalez A, Maradit-Kremers H, Crowson CS, Nicola PJ, Davis JM 3rd, Therneau TM, et al.  The widening mortality gap between rheumatoid arthritis patients and the general population. Arthritis Rheum 2007; 56:3583-7.
  3. Aviña-Zubieta JA, Choi HK, Sadatsafavi M, Etminan M, Esdaile JM, Lacaille D. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum 2008; 59:1690-7.
  4. Panoulas VF, Metsios GS, Pace AV, John H, Treharne GJ, Banks MJ, et al. Hypertension in rheumatoid arthritis. Rheumatology (Oxford) 2008; 47:1286-98.
  5. Toms TE, Symmons DP, Kitas GD. Dyslipidaemia in rheumatoid arthritis: the role of inflammation, drugs, lifestyle and genetic factors. Curr Vasc Pharmacol 2010; 8:301-26.
  6. Metsios GS, Stavropoulos-Kalinoglou A, Panoulas VF, Sandoo A, Toms TE, Nevill  AM, et al. Rheumatoid cachexia and cardiovascular disease. Clin Exp Rheumatol 2009; 27:985-8.
  7. Douglas KM, Pace AV, Treharne GJ, Saratzis A, Nightingale P, Erb N, et al. Excess recurrent cardiac events in rheumatoid arthritis patients with acute coronary syndrome. Ann Rheum Dis 2006; 65:348-53.
  8. Kitas GD, Gabriel SE. Cardiovascular disease in rheumatoid arthritis: state of the art and future perspectives. Ann Rheum Dis 2011; 70:8-14.
  9. Gasparyan AY. Cardiovascular risk and inflammation: pathophysiological mechanisms, drug design, and targets. Curr Pharm Des 2012; 18:1447-9.
  10. Mason JC, Libby P. Cardiovascular disease in patients with chronic inflammation: mechanisms underlying premature cardiovascular events in rheumatologic conditions. Eur Heart J 2015; 36:482-9c.
  11. Sandoo A, Veldhuijzen van Zanten JJ, Metsios GS, Carroll D, Kitas GD. Vascular function and morphology in rheumatoid arthritis: a systematic review. Rheumatology (Oxford) 2011; 50:2125-39.
  12. Nurmohamed MT, Kitas G. Cardiovascular risk in rheumatoid arthritis and diabetes: how does it compare and when does it start? Ann Rheum Dis 2011; 70:881-3.
  13. Peters MJ, Symmons DP, McCarey D, Dijkmans BA, Nicola P, Kvien TK, et al.  EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010; 69:325-31.
  14. Arts EE, Popa CD, Den Broeder AA, Donders R, Sandoo A, Toms T, et al. Prediction of cardiovascular risk in rheumatoid arthritis: performance of original and adapted SCORE algorithms. Ann Rheum Dis. 2015 Feb 17
  15. Dessein PH, Semb AG. Could cardiovascular disease risk stratification and management in rheumatoid arthritis be enhanced? Ann Rheum Dis. 2013; 72:1743-6.
  16. Gonzalez-Gay MA, Gonzalez-Juanatey C, Piñeiro A, Garcia-Porrua C, Testa A, Llorca J. High-grade C-reactive protein elevation correlates with accelerated atherogenesis in patients with rheumatoid arthritis. J Rheumatol.2005; 32:1219-23.
  17. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M, et al. Centers for Disease Control and Prevention; American Heart Association. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107:499-511.
  18. Schepers E, Glorieux G, Dhondt A, Leybaert L, Vanholder R. Role of symmetric dimethylarginine in vascular damage by increasing ROS via store-operated calcium  influx in monocytes. Nephrol Dial Transplant 2009; 24:1429-35.
  19. Strobel J, Mieth M, Endress B, Auge D, König J, Fromm MF, Maas R. Interaction  of the cardiovascular risk marker asymmetric dimethylarginine (ADMA) with the human cationic amino acid transporter 1 (CAT1). J Mol Cell Cardiol 2012; 53:392-400.
  20. Wang Z, Tang WH, Cho L, Brennan DM, Hazen SL. Targeted metabolomic evaluation  of arginine methylation and cardiovascular risks: potential mechanisms beyond nitric oxide synthase inhibition. Arterioscler Thromb Vasc Biol 2009; 29:1383-91.
  21. Siegerink B, Maas R, Vossen CY, Schwedhelm E, Koenig W, Böger R, et al. Asymmetric and symmetric dimethylarginine and risk of secondary cardiovascular disease events and mortality in patients with stable coronary heart disease: the KAROLA follow-up study. Clin Res Cardiol 2013; 102:193-202.
  22. Böger RH, Maas R, Schulze F, Schwedhelm E. Asymmetric dimethylarginine (ADMA) as a prospective marker of cardiovascular disease and mortality--an update on patient populations with a wide range of cardiovascular risk. Pharmacol Res 2009; 60:481-7.
  23. Gürel E, Tigen K, Karaahmet T, Geçmen C, MutluB, Başaran Y. Predictive value of plasma asymmetric dimethylarginine, homocysteine, and high-sensitive CRP levels in occult coronary artery disease: A multidetector-row computed tomography study. Herz 2013; 40:495-501.
  24. Hafner F, Kieninger A, Meinitzer A, Gary T, Froehlich H, Haas E, et al. Endothelial dysfunction and brachial intima-media thickness: long term cardiovascular risk with claudication related to peripheral arterial disease: a prospective analysis. PLoS One 2014; 9:e93357.
  25. Levin A, Rigatto C, Brendan B, Madore F, Muirhead N, Holmes D, et al. CanPREDDICT investigators. Cohort profile: Canadian study of prediction of death, dialysis and interim cardiovascular events (CanPREDDICT). BMC Nephrol 2013; 14:121.
  26. Böger RH, Sullivan LM, Schwedhelm E, et al. Plasma asymmetric dimethylarginine and incidence of cardiovascular disease and death in the community. Circulation 2009; 119:1592-600.
  27. Schulze F, Carter AM, Schwedhelm E, Ajjan R, Maas R, von Holten RA, et al. Symmetric dimethylarginine predicts all-cause mortality following ischemic stroke. Atherosclerosis 2010; 208:518-23.
  28. Meinitzer A, Kielstein JT, Pilz S, Drechsler C, Ritz E, Boehm BO, Winkelmann BR, März W. Symmetrical and asymmetrical dimethylarginine as predictors for mortality in patients referred for coronary angiography: the Ludwigshafen Risk and Cardiovascular Health study. Clin Chem 2011; 57:112-21.
  29. Cavalca V, Veglia F, Squellerio I, De Metrio M, Rubino M, Porro B, et al. Circulating levels of dimethylarginines, chronic kidney  disease and long-term clinical outcome in non-ST-elevation myocardial infarction. PLoS One 2012; 7:e48499.
  30. Kiechl S, Lee T, Santer P, Thompson G, Tsimikas S, Egger G, et al. Asymmetric and symmetric dimethylarginines are of similar predictive value for cardiovascular risk in the general population. Atherosclerosis 2009; 205:261-5.
  31. Ahmetaj-Shala B, Kirkby NS, Knowles R, Al'Yamani M, Mazi S, Wang Z, et al. Evidence that links loss of cyclooxygenase-2 with increased asymmetric dimethylarginine: novel explanation of cardiovascular side effects associate with anti-inflammatory drugs. Circulation 2015; 131:633-42.
  32. Dimitroulas T, Sandoo A, Kitas GD. Asymmetric dimethylarginine as a surrogate marker of endothelial dysfunction and cardiovascular risk in patients with systemic rheumatic diseases. Int J Mol Sci 2012; 13:12315-35.
  33. Sukriti S, Tauseef M, Yazbeck P, Mehta D. Mechanisms regulating endothelial permeability. Pulm Circ 2014; 4:535-51.
  34. Sandoo A, van Zanten JJ, Metsios GS, Carroll D, Kitas GD. The endothelium and its role in regulating vascular tone. Open Cardiovasc Med J 2010; 4:302-12.
  35. Arnal JF, Dinh-Xuan AT, Pueyo M, Darblade B, Rami J. Endothelium-derived nitric oxide and vascular physiology and pathology. Cell Mol Life Sci 1999; 55:1078-87.
  36. Förstermann U, Münzel T. Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation 2006; 113:1708-14.
  37. Hadi HA, Carr CS, Al Suwaidi J. Endothelial dysfunction: cardiovascular risk factors, therapy, and outcome. Vasc Health Risk Manag 2005; 1:183-98.
  38. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002; 105:1135–43.
  39. Vallance P, Leiper J. Cardiovascular biology of the asymmetric dimethylarginine: dimethylarginine dimethylaminohydrolase pathway.  Arterioscler Thromb Vasc Biol 2004; 24:1023-30.
  40. Anthony S, Leiper J, Vallance P. Endogenous production of nitric oxide synthase inhibitors. Vasc Med. 2005; Suppl 1:S3-9.
  41. Tsikas D, Sandmann J, Savva A, Luessen P, Böger RH, Gutzki FM, et al. Assessment of nitric oxide synthase activity in vitro and in vivo by  gas chromatography-mass spectrometry. J Chromatogr B Biomed Sci Appl 2000; 742:143-53.
  42. Leiper JM. The DDAH-ADMA-NOS pathway. Ther Drug Monit 2005; 27:744-6.
  43. Arrigoni F, Ahmetaj B, Leiper J. The biology and therapeutic potential of the DDAH/ADMA pathway. Curr Pharm Des 2010; 16:4089-102.
  44. Kielstein JT, Salpeter SR, Bode-Boeger SM, Cooke JP, Fliser D. Symmetric dimethylarginine (SDMA) as endogenous marker of renal function--a meta-analysis.  Nephrol Dial Transplant 2006; 21:2446-51.
  45. Anderssohn M, McLachlan S, Lüneburg N, Robertson C, Schwedhelm E, Williamson RM, Strachan MW, Ajjan R, Grant PJ, Böger RH, Price JF. Genetic and environmental determinants of dimethylarginines and association with cardiovascular disease in patients with type 2 diabetes. Diabetes Care 2014; 37:846-54.
  46. Seppälä I, Kleber ME, Lyytikäinen LP, Hernesniemi JA, Mäkelä KM, Oksala N, et al. Athero Remo Consortium. Genome-wide association study on dimethylarginines reveals novel AGXT2 variants associated with heart rate variability but not with overall mortality. Eur Heart J 2014; 35:524-31.
  47. Ogawa T, Kimoto M, Sasaoka K. Occurrence of a new enzyme catalyzing the direct conversion of NG,NG-dimethyl-L-arginine to L-citrulline in rats. Biochem Biophys Res Commun 1987;148:671-7.
  48. Jacobi J, Maas R, Cardounel AJ, Arend M, Pope AJ, Cordasic N, et al. Dimethylarginine dimethylaminohydrolase overexpression ameliorates atherosclerosis in apolipoprotein E-deficient mice by lowering asymmetric dimethylarginine. Am J Pathol 2010; 176:2559-70.
  49. Smirnova IV, Kajstura M, Sawamura T, Goligorsky MS. Asymmetric dimethylarginine upregulates LOX-1 in activated macrophages: role in foam cell formation. Am J Physiol Heart Circ Physiol 2004; 287:H782-90.
  50. Chen M, Li Y, Yang T, Wang Y, Bai Y, Xie X. ADMA induces monocyte adhesion via activation of chemokine receptors in cultured THP-1 cells. Cytokine 2008; 43:149-59.
  51. Thum T, Tsikas D, Stein S, Schultheiss M, Eigenthaler M, Anker SD, et al. Suppression of endothelial progenitor cells in human coronary artery disease by the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine. J Am Coll Cardiol 2005; 46:1693-701.
  52. Miyazaki H, Matsuoka H, Cooke JP, Usui M, Ueda S, Okuda S, et al. Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation 1999; 99:1141-6.
  53. Riccioni G, Scotti L, D'Orazio N, Gallina S, Speziale G, Speranza L, Bucciarelli T. ADMA/SDMA in elderly subjects with asymptomatic carotid atherosclerosis: values and site-specific association. Int J Mol Sci 2014; 15:6391-8.
  54. Kielstein JT, Bode-Böger SM, Frölich JC, Ritz E, Haller H, Fliser D. Asymmetric dimethylarginine, blood pressure, and renal perfusion in elderly subjects. Circulation 2003; 107:1891-5.
  55. Böger RH, Bode-Böger SM, Szuba A, Tsao PS, Chan JR, Tangphao O, Blaschke TF, Cooke JP. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 1998; 98:1842-7.
  56. Stühlinger MC, Stanger O. Asymmetric dimethyl-L-arginine (ADMA): a possible link between homocyst(e)ine and endothelial dysfunction. Curr Drug Metab 2005; 6:3-14.
  57. Wilson AM, Shin DS, Weatherby C, Harada RK, Ng MK, Nair N, et al. Asymmetric dimethylarginine correlates with measures of disease severity, major adverse cardiovascular events and all-cause mortality in patients with peripheral arterial disease. Vasc Med 2010; 15:267-74.
  58. Zoccali C, Mallamaci F, Maas R, Benedetto FA, Tripepi G, Malatino LS, et al.; CREED Investigators. Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients. Kidney Int 2002; 62:339-45.
  59. Zairis MN, Patsourakos NG, Tsiaousis GZ, Theodossis Georgilas A, Melidonis A, et al. Plasma asymmetric dimethylarginine and mortality in patients with acute decompensation of chronic heart failure. Heart 2012; 98:860-4.
  60. Napora M, Graczykowska A, Próchniewska K, Zdrojewski Z, Całka A, Górny J, et al. Relationship between serum asymmetric dimethylarginine and left ventricular structure and function in patients with end‑stage renal disease treated with hemodialysis. Pol Arch Med Wewn 2012; 122:226-34.
  61. Szuba A, Podgórski M. Asymmetric dimethylarginine (ADMA) a novel cardiovascular risk factor--evidence from epidemiological and prospective clinical trials. Pharmacol Rep 2006; Suppl:16-20.
  62. Staniszewska A, Rajagopalan S, Al-Shaheen A, Thies F, Brittenden J. Increased levels of symmetric dimethyl-arginine are associated with all-cause mortality in patients with symptomatic peripheral arterial disease. J VascSurg 2015; 61:1292-8.
  63. Chen S, Li N, Deb-Chatterji M, Dong Q, Kielstein JT, Weissenborn K, Worthmann et al. Asymmetric dimethylarginine as marker and mediator in ischemic stroke. Int J MolSci 2012; 13:15983-6004.
  64. Sen D, González-Mayda M, Brasington RD Jr. Cardiovascular disease in rheumatoid arthritis. Rheum Dis Clin North Am 2014; 40:27-49.
  65. Avina-Zubieta J, Thomas J, Sadatsafavi M, et al. Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis 2012; 71:1524–9.
  66. Douglas KM, Pace AV, Treharne GJ, et al. Excess recurrent cardiac events in rheumatoid arthritis patients with acute coronary syndrome. Ann Rheum Dis 2006; 65:348–53.
  67. John H, Kitas GD. Inflammatory arthritis as a novel risk factor for cardiovascular disease. Eur J Intern Med 2012; 23:575-9.
  68. John H, Toms TE, Kitas GD. Rheumatoid arthritis: is it a coronary heart disease equivalent? Curr Opin Cardiol 2011; 26:327-33.
  69. Libby P. Role of inflammation in atherosclerosis associated with rheumatoid arthritis. Am J Med. 2008; 121(10 Suppl 1):S21-31.
  70. John H, Kitas G, Toms T, Goodson N. Cardiovascular co-morbidity in early rheumatoid arthritis. Best Pract Res Clin Rheumatol 2009; 23:71-82.
  71. Stevens RJ, Douglas KM, Saratzis AN, Kitas GD. Inflammation and atherosclerosis in rheumatoid arthritis. Expert Rev Mol Med 2005; 7:1-24.
  72. Prati C, Demougeot C, Guillot X, Godfrin-Valnet M, Wendling D. Endothelial dysfunction in joint disease. Joint Bone Spine 2014; 81:386-91.
  73. Emerging Risk Factors Collaboration, Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 2010; 375:132-40.
  74. MA Gonzalez-Gay, C Gonzalez-Juanatey, A Piñeiro, C Garcia-Porrua, A Testa,  J Llorca. High-grade C-reactive protein elevation correlates with accelerated atherogenesis in patients with rheumatoid arthritis. J Rheumatol 2005; 32:1219-1223.
  75. Maradit-Kremers H, Nicola PJ, Crowson CS, Ballman KV, Jacobsen SJ, Roger VL, et al. Raised erythrocyte sedimentation rate signals heart failure in patients with rheumatoid arthritis. Ann Rheum Dis 2007; 66:76-80.
  76. Maradit-Kremers H, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum 2005; 52:722-32.
  77. Maradit-Kremers H, Nicola PJ, Crowson CS, O'Fallon WM, Gabriel SE. Patient, disease, and therapy-related factors that influence discontinuation of disease-modifying antirheumatic drugs: a population-based incidence cohort of patients with rheumatoid arthritis. J Rheumatol 2006; 33:248-55.
  78. López-Longo FJ, Oliver-Miñarro D, de la Torre I, González-Díaz de Rábago E, Sánchez-Ramón S, Rodríguez-Mahou M, et al. Association between anti-cyclic citrullinated peptide antibodies and ischemic heart disease in patients with rheumatoid arthritis. Arthritis Rheum 2009; 61:419-24.
  79. Surdacki A, Martens-Lobenhoffer J, Wloch A, Marewicz E, Rakowski T, Wieczorek-Surdacka E, et al.  Elevated plasma asymmetric dimethyl-L-arginine levels are linked to endothelial progenitor cell depletion and carotid atherosclerosis in rheumatoid arthritis. Arthritis Rheum 2007; 56:809-19.
  80. Sandoo A, Dimitroulas T, Veldhuijzen van Zanten JJ, Smith JP, Metsios GS, Nightingale P, et al. Lack of association between asymmetric dimethylarginine and in vivo microvascular and macrovascular endothelial function in patients with rheumatoid arthritis. Clin Exp Rheumatol 2012; 30:388-96.
  81. Klimek E, Skalska A, Kwaśny-Krochin B, Surdacki A, Sulicka J, Korkosz M, et al. Differential associations of inflammatory and endothelial biomarkers with disease activity in rheumatoid arthritis of short duration. Mediators Inflamm 2014; 2014:681635.
  82. Di Franco M, Spinelli FR, Metere A, Gerardi MC, Conti V, Boccalini F, et al. Serum levels of asymmetric dimethylarginine and apelin as potential markers of vascular endothelial dysfunction in early rheumatoid arthritis. Mediators Inflamm.2012; 2012:347268.
  83. Włoch A, Wieczorek-Surdacka E, Sulicka-Grodzicka J, Kruszelnicka O, Surdacki A. Asymmetric dimethylarginine reflects cumulative inflammatory burden in rheumatoid arthritis. Rheumatology (Oxford) 2015; 54:1135-6.
  84. Leiper J, Murray-Rust J, McDonald N, Vallance P. S-nitrosylation of dimethylarginine dimethylaminohydrolase regulates enzyme activity: further interactions between nitric oxide synthase and dimethylarginine dimethylaminohydrolase. Proc Natl Acad Sci U S A. 2002; 99:13527-32.
  85. Karbach S, Wenzel P, Waisman A, Munzel T, Daiber A. eNOS uncoupling in cardiovascular diseases--the role of oxidative stress and inflammation. Curr Pharm Des 2014; 20:3579-94.
  86. Dimitroulas T, Sandoo A, Hodson J, Smith J, Panoulas VF, Kitas GD. Relationship between dimethylarginine dimethylaminohydrolase gene variants and asymmetric dimethylarginine in patients with rheumatoid arthritis. Atherosclerosis 2014; 237:38-44.
  87. Surdacki A, Martens-Lobenhoffer J, Wloch A, Gluszko P, RakowskiT, Dubiel JS, et al. Plasma asymmetric dimethylarginine is related to anticitrullinated protein antibodies in rheumatoid arthritis of short duration. Metabolism 2009; 58:316-8.
  88. Korkosz M, Sulicka J, Surdacki A. Dimethylated L-arginine analogues versus autoantibodies in early rheumatoid arthritis. Scand J Rheumatol 2012; 41:82-3.
  89. Kwaśny-Krochin B, Głuszko P, Undas A. Plasma asymmetric dimethylarginine in active rheumatoid arthritis: links with oxidative stress and inflammation. Pol Arch Med Wewn2012; 122:270-6.
  90. Sandoo A, Kitas GD. Current perspectives on the assessment of vascular function and morphology in rheumatoid arthritis. Int J Clin Rheumatol 2013;8:1-3.
  91. Sandoo A, Dimitroulas T, Hodson J, Smith JP, Douglas KM, Kitas GD. Cumulative inflammation associates with asymmetric dimethylarginine in rheumatoid arthritis: a 6 year follow-up study. Rheumatology (Oxford) 2015; 54:1145-52.
  92. Dimitroulas T, Hodson J, Sandoo A, Smith JP, Douglas KM et al. Symmetric Dimethylarginine Is Not Associated with Cumulative Inflammatory Load or Classical Cardiovascular Risk Factors in Rheumatoid Arthritis: A 6-Year Follow-Up Study. Mediators of Inflammation 2015 Article ID 796562, In press.
  93. Turiel M, Atzeni F, Tomasoni L, de Portu S, Delfino L, Bodini BD, et al. Non-invasive assessment of coronary flow reserve and ADMA levels: a case-control study of early rheumatoid arthritis patients. Rheumatology (Oxford) 2009; 48:834-9.
  94. Sandoo A, Hodson J, Douglas KM, Smith JP, Kitas GD: The association between functional and morphological assessments of endothelial function in patients with rheumatoid arthritis: a cross-sectional study. Arthritis Res Ther 2013; 15:R107.
  95. Barbhaiya M, Solomon DH. Rheumatoid arthritis and cardiovascular disease: an update on treatment issues. Curr Opin Rheumatol.2013; 25:317-24.
  96. Sandoo A, Dimitroulas T, Toms TE, Hodson J, Veldhuijzen van Zanten JJ, Smith  JP, et al. Clinical remission following treatment with tumour necrosis factor-alpha antagonists is not accompanied by changes in asymmetric dimethylarginine in patients with rheumatoid arthritis. Clin Biochem 2012; 45:1399-403.
  97. Turiel M, Tomasoni L, Sitia S, Cicala S, Gianturco L, Ricci C, et al. Effects of long-term disease-modifying antirheumatic drugs on endothelial function in patients with early rheumatoid arthritis. Cardiovasc Ther 2010; 28:e53-64.
  98. Angel K, Provan SA, Mowinckel P, Seljeflot I, Kvien TK, Atar D. The L-arginine/asymmetric dimethylarginine ratio is improved by anti-tumor necrosis factor-α therapy in inflammatory arthropathies. Associations with aortic stiffness. Atherosclerosis 2012; 225:160-5.
  99. Bilecik NA, Tuna S, Samancı N, Balcı N, Akbaş H. Prevalence of metabolic syndrome in women with rheumatoid arthritis and effective factors. Int J Clin Exp Med 2014; 7:2258-65.
  100. Ferraccioli G, Gremese E. Adiposity, joint and systemic inflammation: the additional risk of having a metabolic syndrome in rheumatoid arthritis. Swiss Med Wkly 2011; 141:w13211.
  101. Lindhardsen J, Ahlehoff O, Gislason GH, Madsen OR, Olesen JB, Torp-Pedersen C, et al. The risk of myocardial infarction in rheumatoid arthritis and diabetes mellitus: a Danish nationwide cohort study. Ann Rheum Dis 2011; 70:929-34.
  102. Stamatelopoulos KS, Kitas GD, Papamichael CM, Chryssohoou E, Kyrkou K, Georgiopoulos G, et al. Atherosclerosis in rheumatoid arthritis versus diabetes: a comparative study. Arterioscler Thromb Vasc Biol 2009; 29:1702-8.
  103. Dimitroulas T, Sandoo A, Veldhuijzen van Zanten JJ, Smith JP, Hodson J, Metsios GS, et al. Predictors of asymmetric dimethylarginine levels in patients with rheumatoid arthritis: the role of insulin resistance. Scand J Rheumatol.2013; 42:176-81.
  104. Surdacki A, Kruszelnicka O, Rakowski T, Jaźwińska-Kozuba A, Dubiel JS. Asymmetric dimethylarginine predicts decline of glucose tolerance in men with stable coronary artery disease: a 4.5-year follow-up study. Cardiovasc Diabetol 2013; 12:64.
  105. Dimitroulas T, Hodson J, Sandoo A, Smith J, Kitas GD. Symmetric dimethylarginine (SDMA) serum levels in rheumatoid arthritis: correlations with insulin resistance and disease activity scores. Amino Acids. 2015 Mar 13. [Epub ahead of print]
  106. Zsuga J, Török J, Magyar MT, Valikovics A, Gesztelyi R, Lenkei A, et al. Dimethylarginines at the crossroad of insulin resistance and atherosclerosis. Metabolism 2007; 56:394-9.
  107. Anderssohn M, Schwedhelm E, Lüneburg N, Vasan RS, Böger RH. Asymmetric dimethylarginine as a mediator of vascular dysfunction and a marker of cardiovascular disease and mortality: an intriguing interaction with diabetes mellitus. DiabVasc Dis Res 2010; 7:105-18.
  108. Dimitroulas T, Sandoo A, Smith JP, Kitas GD. Asymmetric dimethylarginine is not associated with subendocardial viability ratio in Rheumatoid Arthritis. Int J Cardiol 2014; 172:285-6.